COVID rates after vaccination are relatively low and cases mild in patients with multiple sclerosis treated with disease-modifying therapies – but vaccine antibody response is lower with anti-CD20 therapies.
The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.
Data show statistically significant changes in 29-item MS Impact Scale and the Godin Leisure-Time Exercise Questionnaire scores with the MSAC wellness program
In a new study of more than 600 patients with multiple sclerosis, about 1 in 25 faced a potentially severe drug-drug interaction, with more having at least one potentially risky interaction.
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.